Technology transfer / Localization · GCC · Announced 16 Sept 2026

Local Content and Government Procurement Authority → SPIMACO

SPIMACO has signed a cooperation agreement with Saudi Arabia's Local Content and Government Procurement Authority to localize manufacturing of aflibercept, the retinal-disease biologic, in the Kingdom.

Parties: Local Content and Government Procurement Authority (LCGPA) (Saudi Arabia) → SPIMACO (Saudi Arabia)

Value
Undisclosed
Territory
Saudi Arabia
Therapeutic area
Ophthalmology
Asset
Aflibercept
Announced
16 Sept 2026

Our analysis

Why this matters

SPIMACO (Saudi Pharmaceutical Industries and Medical Appliances Corp.) signed a cooperation agreement with the Local Content and Government Procurement Authority (LCGPA) to localize the manufacture of aflibercept in Saudi Arabia. The agreement was signed on the sidelines of the RGMBS 2026 event in Riyadh (14–16 September 2026). Value, manufacturing stages, site, capacity and start dates were not disclosed.

Aflibercept is one of the highest-value biologics in ophthalmology, used for wet age-related macular degeneration and diabetic macular edema, and biosimilar versions are now entering markets worldwide. Bringing its manufacture into the Kingdom with the procurement authority as counterparty signals that biosimilars, not only small-molecule generics, are now inside the scope of Saudi localization.

The full analysis is free to read with a work email on this page.

Source: Dawaa News MENA

More deals involving Local Content and Government Procurement Authority or SPIMACO

Latest deals

All GCC deals → · All technology transfer / localization deals → · Browse all emerging-market pharma deals →